Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02914535 · ClinicalTrials.gov registry record · Phase 3
Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis
A Phase 3 study of Ulcerative Colitis, sponsored by Alfasigma S.p.A..
- Active
- Registry status
- Phase 3
- Development phase
- 1,173
- Enrollment target
- 20
- Study locations
NCT02914535: Active Phase 3 study of Ulcerative Colitis, sponsored by Alfasigma S.p.A..
NCT02914535 is a Phase 3 study of Ulcerative Colitis that is active but no longer recruiting, run by Alfasigma S.p.A.. The registered enrollment target is 1,173 participants, below the 2,048-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (43% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02914535, a Phase 3 study of Ulcerative Colitis, is active but no longer recruiting, sponsored by Alfasigma S.p.A..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,173 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in ulcerative colitis (UC).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Filgotinib
Study Locations (20)
Florida
- UF Clinical Research Center - Gainesville
- Florida Research Institute - Lakewood Rch
- University of Miami Crohn's and Colitis Center - Miami
- Cordova Research Institute - Miami
- Gastroenterology Group of Naples - Naples
- Advanced Medical Research Center - Port Orange
- Tampa General Hospital - Tampa
- Florida Medical Clinic, P.A - Zephyrhills
Georgia
- Gastroenterology Associates Of Central Georgia, LLC - Macon
- Gastrointestinal Specialists of Georgia - Marietta
- Atlanta Gastroenterology Specialist, PC - Suwanee
California
- VA Long Beach Healthcare System - Long Beach
- Cedars Sinai Medical Center - Los Angeles
Alabama
- Digestive Health Specialists Of The Southeast - Dothan
Arizona
- Mayo Clinic Arizona - Scottsdale
Colorado
- South Denver Gastroenterology, PC - Lone Tree
Connecticut
- Connecticut GI PC-Research Division - Farmington
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,173 participants |
| Start Date | 2017-02-23 |
| Est. Completion | 2026-09 |
| Phase | Phase 3 |
What the registry record for NCT02914535 still lists
NCT02914535 is an interventional study that assigns participants to a tested intervention. Its 1,173 participants enrollment target places it among the larger protocols in the corpus, below the 2,048-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (43% lower).
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02914535 names 20 study sites across 10 states, led by Florida, Georgia, California.
Frequently Asked Questions
What is clinical trial NCT02914535 about?
NCT02914535 is a clinical study titled "Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis". The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in ulcerative colitis (UC).
What is the current status of trial NCT02914535?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,173 participants. The study started on 2017-02-23. Estimated completion is 2026-09.
What conditions does trial NCT02914535 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT02914535?
The interventions under investigation include: Placebo (DRUG), Filgotinib (DRUG).
Who is sponsoring clinical trial NCT02914535?
This trial is sponsored by Alfasigma S.p.A., which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02914535 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02914535's enrollment target sits among peer trials
1,173 6th of 122 higher than 117 of 122 other Ulcerative Colitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ulcerative Colitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 3
-
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
RECRUITING · Phase 3
-
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
RECRUITING · Phase 3
-
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 3
-
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
RECRUITING · Phase 3
-
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04275557 · 1,174 participants
Using Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas
- NCT06133322 · 1,176 participants · NA
Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED)
- NCT06469788 · 1,170 participants · NA
Testimonials and Navigation in Rheumatology
- NCT05688436 · 1,178 participants
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI